As we celebrate the Queen’s Platinum Jubilee it was great to see the King and Queen of Sweden visiting AstraZeneca in Cambridge last week. The visit provided the platform for the UK government to sign its first Memorandum of Understanding (MoU) with Sweden regarding life sciences. The MoU promises to lead to "enhancing cooperation between our governments and to galvanise our life sciences ecosystems in working together on our shared strengths and common priorities, covering fields from precision medicine, clinical trials, pandemic preparedness and antimicrobial resistance to sustainability, trade, and investment for the sector."
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced the appointment of Dr Paul Brooks as Chief Business Officer.
The RSA Group, a leading life sciences executive search firm, has published the latest of its Talent Equity® Reports: Biosimilars 2022. The new report features interviews with leaders of biosimilars companies who give their unique insights into the challenges and opportunities facing this fast-growing sector and the leadership needed to grow the industry, including the power of creating strong in-house knowledge and evaluating where this talent already exists.
Coulter Partners, the global experts in Executive Search and Leadership Development in Life Sciences, Health, and Tech, recently partnered with Helsinn Group, a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and was pleased to secure the appointment of Dr Melanie Rolli as Group Chief Operating Officer (COO).
Coulter Partners, the global experts in Executive Search and Leadership Development in Life Sciences, Health, and Tech, recently partnered with Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, and are pleased to announce the placement of J.D. Mowery as Chief Operating Officer (COO).